Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins Report

Pre-Reading Paragraph

With Medicare introduced in the US in the early 1960’s, the insurance industry recorded its ever-largest change in the entire history. This was because of the advent by economists that the introduction of Medicare would result into inventions within the pharmaceutical industry. This would as a result add onto the mortality rates reduction of the citizens.

The new inventions are regarded as saviors in terms of reduction in the cost of medication; prolonged life hence a longer life expectancy accompanied with lowered mortality rates. It is therefore prudent to do an investigation on whether Medicare introduction made way for the inventions in the pharmaceutical industries.

Furthermore, a thorough assessment and judgment is conducted to establish a proof of the well-intended intentions of the pharmaceutical innovation products concerning extending lifespan. Invention of new technology through all the fields had proved to prolong life since it presents a new outlook to peoples’ view towards life hence a bust in the living standards.

This is explained in the article alongside the value and impact it has on the socio-economic sphere. As a result, “Can we live forever?” is a question that is tackled all around in details and with all the relevant proofs and disapprovals presented. Author and the article The author of the article is a professor at York University in Toronto.

The article is the latest dated 2010 and originally sourced from the Social Science & Medicine 2010. (70). The author has received several awards ranging from; Dean’s award for established researchers in 2008 from York University, Research excellence award from the University of Toronto in 2004 to SWAB award in 2004 again.

The article is a highly informative one; it is about the most modern inventions in the therapeutic field and their relevance to the new molecular entities and GDP combined. This is in conjunction to their impacts on life expectancy and mortality rates. The content is derived from the rich experience that the author has gained from consultancy about pharmaceutical issues for several governments and institutions such as the world health organization (WHO).

The author also has vast research interests on approval systems and the population apart from his field of the pharmaceuticals. Striking or memorable factual evidence The first factual evidence is about all the new molecular enterprises (NME’s), the main issues behind them is their prospects advancing as time and new inventions occur.

The striking and astonishing bit is that they become even more weaker as new inventions are realized e.g. the recently invented angiotensin converting enzyme(ACE) inhibitor has shown more efficiency as compared to the latest series of the same enzyme. This conclusion is made after finding out about the benefits presented by the former in the last 40 years. Secondly, the most recent inventions do not add onto the life expectancy; they are mere inventions in sectors that are not relevant to either mortality rates or life expectancy.

This is from the previously mentioned irrelevant inventions such as those directed towards treatments of toenails and those to minimize baldness, which do not at any cost relate to facilitating favorable mortality rates and life expectancy. An example of an older invention that still facilitates mortality is the aspirin; it decreases mortality from cardio and cerebrovascular disease.

Challenge from the article As shown in the data by Schnittker and Karandinos indicating mortality to be greater in the age bracket 15-19 years. The major challenge comes in explaining the causes of mortality in this age bracket, a further challenge comes in explaining the causes identified. From this article; either causes are identified and categorized as identifiable causes or unidentifiable, some of these causes can be avoided while a majority cannot be prevented hence very costly.

Prevention and control of these diseases to facilitate mortality and life expectancy is another challenge that remains a mystery. This is due to the fact of the difficulties posed in terms of resource constraints. Therefore, this has rendered research in the field useless since it provides less to death minimization. Contribution of the article to the field of knowledge The article was meant to answer the hypothesis of whether life can be prolonged as a result of inventions.

The article has therefore added into the field of knowledge by trying to explain the relationship that exists between the inventions in the field of medicine and life expectancy. It has also inputted positively by giving an explanation on how the GDP is related to mortality rates. The article explains that the more inventions we have on drugs, the more life we are likely to have. Drugs are as a result vital and the world population therefore needs advance in the field of medicine more.

The article stresses the need of encouraging more inventions and innovations. This is despite the fact that life can never be there forever. The article has also presented the view by economists supporting the introduction of Medicare, its facilitation for pharmaceutical inventions hence an impetus for the development of the current drugs which further extend into life expectancy.

This report on Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins was written and submitted by your fellow student. You are free to use it for research and reference purposes in order to write your own paper; however, you must cite it accordingly.

IvyPanda. (2019, April 5). Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins. Retrieved from https://ivypanda.com/essays/pharmaceutical-innovation-can-we-live-forever-a-commentary-on-schnittker-and-karandins/

Work Cited

"Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins." IvyPanda, 5 Apr. 2019, ivypanda.com/essays/pharmaceutical-innovation-can-we-live-forever-a-commentary-on-schnittker-and-karandins/.

1. IvyPanda. "Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins." April 5, 2019. https://ivypanda.com/essays/pharmaceutical-innovation-can-we-live-forever-a-commentary-on-schnittker-and-karandins/.

Bibliography

IvyPanda. "Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins." April 5, 2019. https://ivypanda.com/essays/pharmaceutical-innovation-can-we-live-forever-a-commentary-on-schnittker-and-karandins/.

References

IvyPanda. 2019. "Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins." April 5, 2019. https://ivypanda.com/essays/pharmaceutical-innovation-can-we-live-forever-a-commentary-on-schnittker-and-karandins/.

References

IvyPanda. (2019) 'Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandins'. 5 April.

This is IvyPanda's free database of academic paper samples. It contains thousands of paper examples on a wide variety of topics, all donated by helpful students. You can use them for inspiration, an insight into a particular topic, a handy source of reference, or even just as a template of a certain type of paper. The database is updated daily, so anyone can easily find a relevant essay example.